Allogene Therapeutics, Inc.

Contributing Author

Recent Articles by Allogene Therapeutics, Inc.

Jun-01	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO ALLO GlobeNewswire
May-23	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences ALLO GlobeNewswire
May-22	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel ALLO GlobeNewswire
May-13	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update ALLO GlobeNewswire
May-06	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ALLO GlobeNewswire